{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02497508\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["nivolumab"]],"indication":"recurrent malignant pleural mesothelioma","name":"NivoMes","nct_id":"NCT02497508","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nivomes-nct02497508. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"NivoMes","arms":[{"description":"Nivolumab will be administered 2 weekly by intravenous infusion in a dose of 3 mg/kg","label":"Nivolumab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2017-07","type":"ACTUAL"},"conditions":["Malignant Pleural Mesothelioma"],"enrollment":{"count":33,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"nivolumab","otherNames":["BMS-936558"],"type":"DRUG"}],"last_update":"2017-09-14","lead_sponsor":"The Netherlands Cancer Institute","official_title":"A Single Arm Phase II Study of Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma: Interim Biopsy Analysis to Determine Efficacy. Acronym: NivoMes Study","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2017-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"DCR","timeFrame":"at 12 weeks"}],"references":[{"citation":"Desai AP, Kosari F, Disselhorst M, Yin J, Agahi A, Peikert T, Udell J, Johnson SH, Smadbeck J, Murphy S, Karagouga G, McCune A, Schaefer-Klein J, Borad MJ, Cheville J, Vasmatzis G, Baas P, Mansfield A. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy. J Immunother Cancer. 2023 Jun;11(6):e006035. doi: 10.1136/jitc-2022-006035.","pmid":"37279993","type":"DERIVED"}],"start_date":{"date":"2015-07"},"study_type":"INTERVENTIONAL","title":"Nivolumab in Patients With Recurrent Malignant Mesothelioma","url":"https://clinicaltrials.gov/study/NCT02497508"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nivomes-nct02497508"}